Get the Stockscreener App
3.115
2.94%
0.055
Alvotech stock is traded at $3.115, with a volume of 85,322.
It is up +2.94% in the last 24 hours and down -14.40% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$3.06
Open:
$3.12
24h Volume:
85,322
Relative Volume:
0.12
Market Cap:
$1.05B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
32.31
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
-7.62%
1M Performance:
-14.40%
6M Performance:
-40.68%
1Y Performance:
-67.22%
1-Day Range:
$3.08
$3.24
1-Week Range:
$3.04
$3.57
52-Week Range:
$2.94
$9.94
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.115 | 1.03B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
17.50 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.90 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
530.97 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech Revenue Breakdown – NASDAQ:ALVOW - TradingView
Alvotech (ALVO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (ALVO) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (ALVO) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (ALVO) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (ALVO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (ALVO) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Alvotech Revenue Breakdown – NASDAQ:ALVO - TradingView
TradingKey - TradingKey
Alvotech (ALVO) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (NASDAQ:ALVO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Alvotech SA (ALVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alvotech (NASDAQ:ALVO) Slides as Market Concerns Deepen - Kalkine Media
Alvotech (NASDAQ:ALVO) Stock Price Down 7.8%Here's What Happened - MarketBeat
Inspection Findings Highlight Hurdles Facing Alvotech’s Launch Plans - insights.citeline.com
Alvotech files automatic mixed securities shelf - MSN
ALVO Stock Price Prediction 2025-2026 | Alvotech Forecast - 24/7 Wall St.
Novo, Alvotech face continued scrutiny at plants tied to recent FDA rejections - Fierce Pharma
Alvotech (ALVO) Could Be 76% Below Fair Value On New $75 Million Debt Facility - simplywall.st
Alvotech (NASDAQ:ALVO) Shares Down 5.5%Here's What Happened - MarketBeat
Alvotech (ALVO) Barclays 27th Annual Global Healthcare Conference 2025 Summary - Quartr
ETFs Investing in Alvotech Stocks - TradingView
Enterprise value to EBITDA forward of Alvotech – NASDAQ:ALVO - TradingView
Alvotech (ALVO) Q3 2025 earnings summary - Quartr
Price to earnings forward of Alvotech – NASDAQ:ALVO - TradingView
Enterprise value to revenue forward of Alvotech – NASDAQ:ALVO - TradingView
Price to sales forward of Alvotech – NASDAQ:ALVO - TradingView
Price to book forward of Alvotech – NASDAQ:ALVO - TradingView
Enterprise value to EBIT forward of Alvotech – NASDAQ:ALVO - TradingView
Enterprise value to EBIT forward of Alvotech – SWB:Z45 - TradingView
Alvotech Seeks Launch Momentum From Renewed FDA Push - insights.citeline.com
Alvotech(ALVO) Stock Options Chain | Quotes & News - Moomoo
‘Seeing the evolution’: As branded patent cliff looms, biosimilar experts size up US hurdles, opportunities ahead - Fierce Pharma
Alvotech Q1 2026 slides: revenue dips 20%, EBITDA rises on mix shift - Investing.com
Alvotech (ALVO) Secured $240 Million In New Capital, Is The Stock Cheap? - simplywall.st
Alvotech Warrant 2022-open end on Financial Disclosures & SEC Filings - TradingView
Transactions of Managers and Closely Associated Persons - Yahoo Finance UK
Should Alvotech’s Expanded US$240 Million Capital Access Require Action From Alvotech (ALVO) Investors? - simplywall.st
Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering - Yahoo Finance
Janssen Files BPCIA Complaint Against Alvotech Related To Golimumab Biosimilar - marketscreener.com
Alvotech further strengthens liquidity by securing term loan facility of $75 million - Sahm
Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO) - Yahoo Finance
Alvotech Secures Term Loan Facility of $75MM from GoldenTree Asset Management - ABF Journal
Alvotech announced that it has received $175 million in funding - marketscreener.com
Biotech firm Alvotech expands capital access with $75M term loan facility - MSN
Alvotech (NASDAQ: ALVO) adds $75M term loan, lifting new capital access to $240M - Stock Titan
Alvotech Secures Additional $75 Million Term Loan Facility Led By GoldenTree Asset Management - marketscreener.com
Alvotech Secures Additional $75 Million Term Loan Facility Led by GoldenTree Asset Management Following Recent Equity Raise - Quiver Quantitative
Alvotech adds $75M debt after $165M equity raise - Stock Titan
Alvotech Secures Up to $75 Million Additional Term Loan Facility to Support Pipeline and Global Launches - Quiver Quantitative
Form 13D/A Alvotech For: 30 June By Investing.com - Investing.com Australia
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):